-+ 0.00%
-+ 0.00%
-+ 0.00%

Chi-Med announced that it has submitted an application for the marketing of a new drug in the US for the treatment of MET-driven EGFR mutant lung cancer in combination with Teresa.

智通财经·09/29/2026 00:09:13
语音播报
Chi-Med announced that it has submitted an application for the marketing of a new drug in the US for the treatment of MET-driven EGFR mutant lung cancer in combination with Teresa.